Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of Adeno-Associated Virus Gene Therapy IC-100 for rhodopsin-mediated autosomal dominant Retinitis pigmentosa

Next Previous
Trial Profile

A phase 1/2 study of Adeno-Associated Virus Gene Therapy IC-100 for rhodopsin-mediated autosomal dominant Retinitis pigmentosa

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IC 100 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IVERIC bio

Most Recent Events

  • 02 Nov 2020 According to an IVERIC bio media release, the Company plans to file an IND for IC-100 with the FDA in early 2021.
  • 05 Aug 2020 According to an IVERIC bio media release, the company plans to begin enrollment during the first half of 2021.
  • 27 Feb 2020 According to an IVERIC bio media release, company plans to initiate this phase 1/2 study in fourth quarter of 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top